⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11989255 | 0.83 | MEN1 (0.44) | — | |
| SCHEMBL12967466 | 0.81 | DNM1 (0.46) | — | |
| SCHEMBL14464146 | 0.80 | — | — | |
| SCHEMBL12967471 | 0.79 | DNM1 (0.50) | — | |
| SCHEMBL12967474 | 0.79 | DNM1 (0.50) | — | |
| SCHEMBL15384971 | 0.79 | CA1 (0.34) | — | |
| SCHEMBL2715609 | 0.79 | CA1 (0.48) | — | |
| SCHEMBL48410 | 0.77 | MEN1 (0.42) | — | |
| SCHEMBL245935 | 0.77 | — | — | |
| SCHEMBL1319818 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024015251-A1 | INHIBITORS OF HPK1 AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2022140390-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-3878451-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A JAK-INHIBITING 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINE COMPOUND | Array Biopharma Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| US-11021486-B2 | Coumarin-like cyclic compound as MEK inhibitor and use thereof | CSTONE PHARMACEUTICALS (KY) | 2021-06-01 | — | — | US | disclosed |
| EP-3227297-B1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3750910-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV Healthcare UK(No.4) Limited (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-20200148695-A1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2020-05-14 | — | — | US | disclosed |
| EP-2900660-B1 | HERBICIDAL AND FUNGICIDAL 3-HETEROARYLISOXAZOLIN-5-CARBOXAMIDES AND 3-HETEROARYLISOXAZOLIN-5-THIOAMIDES | BAYER CROPSCIENCE AG (DE) | 2018-01-17 | — | — | EP | disclosed |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20130222738-A1 | COLOR LIQUID CRYSTAL DISPLAY DEVICE | CHI MEI CORPORATION (TW) | 2013-08-29 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080167347-A1 | Antidiabetic, antiproliferative, anticancer agents; benzanilide derivatives | SHIONGI & CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-7271271-B2 | Imidazolo-related compounds, compositions and methods for their use | AMGEN SF, LLC (US) | 2007-09-18 | — | — | US | disclosed |
| US-7202239-B2 | Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1758863-A1 | TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES | AstraZeneca AB (SE) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123685-A1 | TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |